Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

Inclusion Criteria:

- Between 18 and 65 years of age inclusive, at the time of signing the informed consent.

- Healthy as determined by the investigator or medically qualified designee based on a
medical evaluation including medical history, physical examination, laboratory tests
and cardiac evaluation (history and electrocardiogram [ECG]). A subject with a
clinical abnormality or laboratory parameter(s) which is/are not specifically listed
in the inclusion or exclusion criteria, outside the reference range for the population
being studied may be included only if the investigator in consultation with the
Medical Monitor agree and document that the finding is unlikely to introduce
additional risk factors and will not interfere with the study procedures.

- Body weight >= 50 kilogram (kg) for males and >= 45 kg for females and body mass index
(BMI) within the range 18.5 - 31.0 kg per meter square (kg/m^2) (inclusive).

- Male or female. Non-reproductive potential defined as: Pre-menopausal females with one
of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion
procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy;
Documented Bilateral Oophorectomy. Postmenopausal defined as 12 months of spontaneous
amenorrhea [in questionable cases a blood sample with simultaneous follicle
stimulating hormone (FSH) and estradiol levels consistent with menopause]. Females on
hormone replacement therapy (HRT) and whose menopausal status is in doubt will be
required to use one of the highly effective contraception methods if they wish to
continue their HRT during the study. Otherwise, they must discontinue HRT to allow
confirmation of post-menopausal status prior to study enrolment. Reproductive
potential and agrees to follow one of the options listed in the Modified List of
Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential
(FRP) from 30 days prior to the first dose of study medication and until 2 weeks after
dosing with study medication and completion of the follow-up visit.

- Capable of giving signed informed consent which includes compliance with the
requirements and restrictions.

Exclusion Criteria:

- Alanine amino transferase (ALT) and bilirubin >1.5x Upper limit of normal (ULN)
(isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct
bilirubin <35 percent).

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones).

- QT correction using Fridericia Formula (QTcF) >450 Milliseconds (msec).

- Unable to refrain from the use of prescription [that is (i.e. or non-prescription
drugs, including vitamins, herbal and dietary supplements (including St John's Wort)
within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives
(whichever is longer) prior to the first dose of study medication, unless in the
opinion of the Investigator and ViiV Medical Monitor the medication will not interfere
with the study procedures or compromise subject safety.

- History of regular alcohol consumption within 6 months of the study defined as: an
average weekly intake of >14 drinks for males or >7 drinks for females. One drink is
equivalent to 12 gram (g) of alcohol: 12 ounces (360 milliliters [mL]) of beer, 5
ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or
nicotine- containing products within 1 month prior to screening.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or Medical
Monitor, contraindicates their participation.

- Creatinine clearance (CrCL) <90 mL/minute.

- A positive hepatitis B surface antigen (HBsAg) or a positive hepatitis B core antibody
with a negative hepatitis B surface antibody, positive hepatitis C antibody test
result at screening or within 3 months prior to first dose of study treatment.

- A positive pre-study drug/alcohol screen.

- A positive test for Human Immuno-deficiency Virus (HIV) antibody.

- Where participation in the study would result in donation of blood or blood product in
excess of 500 mL within 56 days.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.